9543445

Source:http://linkedlifedata.com/resource/pubmed/id/9543445

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0001675, umls-concept:C0008976, umls-concept:C0020971, umls-concept:C0205390, umls-concept:C0231221, umls-concept:C0442711, umls-concept:C0871489, umls-concept:C1414406, umls-concept:C1963724, umls-concept:C2587213
pubmed:issue	5
pubmed:dateCreated	1998-6-8
pubmed:abstractText	To alter the natural course of HIV-1 infection by inducing or potentiating immune responses to HIV-1 envelope glycoprotein.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8710219
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/AIDS Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/HIV Envelope Protein gp160, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic, http://linkedlifedata.com/resource/pubmed/chemical/VaxSyn HIV-1 (gp160) vaccine, http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	0269-9370
pubmed:author	pubmed-author:AiutiFF, pubmed-author:AmmassariAA, pubmed-author:AntinoriAA, pubmed-author:CarlesimoMM, pubmed-author:GuerraE CEC, pubmed-author:OrtonaLL, pubmed-author:PontesilliOO, pubmed-author:ProzzoAA, pubmed-author:SeeberA CAC, pubmed-author:TamburriniEE, pubmed-author:TominoCC, pubmed-author:VelleWW
pubmed:issnType	Print
pubmed:day	26
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	473-80
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:9543445-AIDS Vaccines, pubmed-meshheading:9543445-Adolescent, pubmed-meshheading:9543445-Adult, pubmed-meshheading:9543445-CD4 Lymphocyte Count, pubmed-meshheading:9543445-CD8-Positive T-Lymphocytes, pubmed-meshheading:9543445-Combined Modality Therapy, pubmed-meshheading:9543445-Double-Blind Method, pubmed-meshheading:9543445-Female, pubmed-meshheading:9543445-HIV Envelope Protein gp160, pubmed-meshheading:9543445-HIV Infections, pubmed-meshheading:9543445-HIV-1, pubmed-meshheading:9543445-Humans, pubmed-meshheading:9543445-Lymphocytes, pubmed-meshheading:9543445-Male, pubmed-meshheading:9543445-Middle Aged, pubmed-meshheading:9543445-RNA, Viral, pubmed-meshheading:9543445-Time Factors, pubmed-meshheading:9543445-Vaccines, Synthetic, pubmed-meshheading:9543445-Viremia, pubmed-meshheading:9543445-Zidovudine
pubmed:year	1998
pubmed:articleTitle	Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults. VaxSyn Protocol Team.
pubmed:affiliation	Department of Clinical Medicine, University of Rome La Sapienza, Italy.
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II